posted
looks like a good candidate for a double bounce to me.. presenting at a biotech confrence on Dec. 13th.. could move
Posts: 2292 | Registered: Mar 2005
| IP: Logged |
The MarketWatch Readers' Choice CEO of the Year contest was open to voting between Nov. 13 and Dec. 5.
The results, in order of votes received:
1. Ramesh Pandey is the chief executive officer and founder of Xechem International Inc.
Xechem International, based in New Jersey and with 15 employees, is the holding company which owns all the capital stock of Xechem Inc., a development stage biopharmaceutical company currently engaged in the research, development and limited production of niche generic and proprietary drugs from natural sources. 2. Steve Jobs, Apple Computer
3. Warren Buffett, Berkshire Hathaway
4. James Sinegal, Costco Wholesale Corp.
5. John Chambers, Cisco Systems Inc.
6. Mark Hurd, Hewlett-Packard Co.
7. Richard Wagoner, General Motors Corp.
8. Matthew Ferguson, CareerBuilder.com
9. John Mack, Morgan Stanley
10. Jeffrey Immelt, General Electric Co.
Posts: 723 | From: MotorCity | Registered: Jun 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Pandey, Jobs, Buffet in that order. Pretty funny actually. Any chance most voters were just us penny players? nah. If only our stock prices were also in that order - xkem being on top vs. bottom of course. Someday!
Posts: 551 | From: FL | Registered: Apr 2006
| IP: Logged |
posted
chart shows bottomed out and oversold.. meaning it should bounce now that selling is over.. simple really
Posts: 2292 | Registered: Mar 2005
| IP: Logged |
posted
I'm holding and willing this to my kids so they can leave it to their kids so they can cash in.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Let's not rush it. I don't think we want to play this like a penny. Like you said Boo this stock is still going to be reeling in profits when our grandkids are born. I'm holding onto this for at least a year.
Posts: 69 | Registered: Dec 2005
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
Xechem CEO Dr. Ramesh Pandey Wins the MarketWatch Readers' Choice 2006 CEO of the Year Award Thursday December 7, 6:30 am ET
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--The Chairman and CEO of Xechem International, Inc. (OTC BB: XKEM - News), Dr. Ramesh Pandey, was named Marketwatch Readers' Choice 2006 CEO of the year, just ahead of Steve Jobs of Apple Computer, with Warren Buffet of Berkshire Hathaway a close third. ADVERTISEMENT
Xechem International had a watershed year in 2006. In July, Xechem successfully launched NICOSAN(TM), its breakthrough drug for the prophylactic management of Sickle Cell Disease in Nigeria. Nigeria has the highest incidence of Sickle Cell Disease in the world, with approximately 4 million people affected. The drug was approved by Nigerian drug regulatory authority NAFDAC, on July 3rd, 2006, and was launched just a few days later at a ceremony in Abuja, Nigeria presided over by His Excellency, Chief Olusegun Obasanjo, the President of Nigeria. NICOSAN(TM) is currently being sold in Nigeria. Xechem is conducting the necessary studies for the submission of an Investigational New Drug (IND) application to the FDA to start Clinical Trials in the USA and Europe in 2007. The year also witnessed the ground-breaking for what will be Xechem's state-of-the-art FDA/cGMP-compliant factory in Abuja for the full commercial scale production of NICOSAN(TM). The facility is scheduled to be operational in 2007.
Dr. Pandey commented, "While I am honored to have won the MarketWatch Readers' Choice 2006 CEO of the Year Award, particularly given the impressive group of accomplished and renowned executives named as finalists for this award, what is really motivating me is how close Xechem International is to making a crucial health difference to millions of sufferers of Sickle Cell Disease, first in Nigeria, and eventually throughout the world. We have made enormous progress toward this goal in 2006, and I want to personally thank MarketWatch's readers for recognizing my efforts by honoring me with this prestigious award. I would also like to thank each and every shareholder for their votes, support and confidence in me."
About NICOSAN(TM)
NICOSAN(TM) is an anti-sickling drug developed by Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM) no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).
-------------------- "Great Day for Up!"....Dr. Seuss Posts: 3387 | Registered: Mar 2006
| IP: Logged |
posted
wow Jo - i thought someone had already posted that! thanks! too many boards out there!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Xechem CEO, Dr. Ramesh Pandey to Present at the 10th Annual New York Society of Security Analysts Biotech/Specialty Pharma Industry Conference Business Wire - December 08, 2006 06:30
NEW BRUNSWICK, N.J., Dec 08, 2006 (BUSINESS WIRE) -- Xechem International, Inc. (OTC BB: XKEM), Dr. Ramesh C. Pandey, the Chairman and CEO of Xechem International, will present at the 10th Annual New York Society of Security Analysts Biotech/Specialty Pharma Industry Conference in New York City on Tuesday, December 12th, 2006. He is scheduled to speak at 3:10 pm (EST). Dr. Pandey's presentation will cover the significant progress in Nigeria for production and distribution of Xechem's recently approved Sickle Cell drug NICOSAN(TM). In addition, Dr. Pandey will discuss Xechem's new Sickle Cell product 5-HMF, a small-molecular compound, which has shown great promise in the preliminary studies with transgenic (Tg) mice, that will be developed as an injectable for acute episodes. Dr. Pandey's presentation will be webcast live through a link on the Xechem website (www.xechem.com).
About NICOSAN(TM)
NICOSAN(TM) is an anti-sickling drug developed by Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM) no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced.
About 5-HMF
5-HMF is a pure natural compound developed by Professor Donald Abraham and his group at Virginia Commonwealth University (VCU). Studies carried out at VCU and Children's Hospital of Philadelphia (CHOP) has shown 5-HMF has high affinity for sickle cell haemoglobin and thus the most promising molecule to treat Sickle Cell Disease (SCD). Preliminary animal studies show that 5-HMF is orally active with high bioavailability and has high red cell membrane permeability with very little, if any, toxicity. Xechem has license for 5-HMF from VCU for research, development, worldwide sales and marketing. Xechem received Orphan Drug Designation for 5-HMF from US-FDA on June 6th, 2006.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties.
SOURCE: Xechem International, Inc.
Xechem International, Inc. Stephen Burg, Director, 707-425-8855
Copyright Business Wire 2006
-------------------- "Great Day for Up!"....Dr. Seuss Posts: 3387 | Registered: Mar 2006
| IP: Logged |
Topic Closed
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
